Evaxion (NASDAQ: EVAX) to present 2026 milestones at Biotech Showcase in SF

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K to furnish a press release about an upcoming investor-focused appearance. The company will present its 2026 milestones and provide a corporate update at the Biotech Showcase conference in San Francisco, which takes place January 12–14, 2026. CEO Helen Tayton-Martin is scheduled to speak on January 13, 2026, at 2:00 p.m. PST in the Yosemite C track. During the same week, which coincides with the J.P. Morgan Healthcare Conference, Evaxion plans to engage with stakeholders and potential business partners in San Francisco. The filing also incorporates this report by reference into several existing Evaxion registration statements, linking the disclosure to its broader U.S. securities offering framework.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On January 7, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: January 7, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion’s 2026 company milestones and provide a company update on January 13, 2026.

The Biotech Showcase conference coincides with the J.P. Morgan Healthcare Conference and Evaxion will engage with stakeholders in San Francisco, including potential business partners, throughout the week.

Presentation details:
Date: Tuesday, January 13, 2026
Time: 2:00pm PST/11:00pm CET
Track: Yosemite C (Ballroom Level)

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What does Evaxion A/S (EVAX) report in this Form 6-K?

Evaxion A/S furnishes a press release stating that CEO Helen Tayton-Martin will present the company’s 2026 milestones and provide a company update at the Biotech Showcase conference in San Francisco in January 2026.

When and where will Evaxion (EVAX) present its 2026 milestones?

Evaxion will present at the Biotech Showcase conference in San Francisco, California, taking place January 12–14, 2026, with the CEO’s presentation scheduled for January 13, 2026, at 2:00 p.m. PST in the Yosemite C track.

How is this Evaxion Form 6-K incorporated into existing SEC registrations?

The Form 6-K is incorporated by reference into Evaxion’s registration statements on Form S-8 and multiple Forms F-3 and F-1, making the information part of those registration statements unless later superseded.

What type of company is Evaxion A/S (EVAX)?

Evaxion A/S is described as a clinical-stage TechBio company that uses its AI-Immunology™ platform and proprietary AI prediction models to develop novel immunotherapies and vaccines for cancer, bacterial diseases, and viral infections.

Who is presenting for Evaxion at the Biotech Showcase conference?

Evaxion’s Chief Executive Officer, Helen Tayton-Martin, will present the company’s 2026 milestones and provide a corporate update on January 13, 2026.

How can investors contact Evaxion’s investor relations team?

Investors can contact Mads Kronborg, Vice President, Investor Relations & Communication at Evaxion, by phone at +45 53 54 82 96 or via email at mak@evaxion.ai.

Does the Evaxion 6-K contain forward-looking statements?

Yes. The announcement includes a forward-looking statement section noting that terms like “expect,” “plan,” and “will” indicate forward-looking statements and highlights risks such as the company’s financial condition, product development, clinical trials, regulation, partnerships, and broader macro-economic factors.